IntelGenx Technologies Corp., a drug delivery company, develops novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers RIZAPORT, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines. The company's products under development comprise INT0001/2004, an anti-hypertension drug; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2012 for schizophrenia; and INT0043/2015 to treat cognitive impairment and Alzheimer's disease. It is also developing various products, including INT0037/2013, INT0039/2013, INT0040/2013, INT0042/2015, INT0036/2013, and INT0044/2016 based on three delivery platform technologies, which consist of VersaFilm, an oral film technology; VersaTab, a multilayer tablet technology; and AdVersa, a mucoadhesive tablet technology. The company has co-development and commercialization agreements with RedHill Biopharma Ltd.; Par Pharmaceutical Companies, Inc.; Endo Ventures Ltd., licensing, development, and supply agreement with Chemo Group; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.
Industry, Sector and Symbol
Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:IGXT
CUSIPN/A
Phone514-331-7440
Debt
Debt-to-Equity Ratio4.56
Current Ratio1.90
Quick Ratio1.90
Price-To-Earnings
Trailing P/E Ratio-16.75
Forward P/E Ratio-4.79
P/E GrowthN/A
Sales & Book Value
Annual Sales$5.20 million
Price / Sales9.15
Cash FlowN/A
Price / CashN/A
Book Value$0.06 per share
Price / Book11.17
Profitability
EPS (Most Recent Fiscal Year)($0.04)
Net Income$-3,050,000.00
Net Margins-202.88%
Return on Equity-214.48%
Return on Assets-51.00%
Miscellaneous
Employees35
Outstanding Shares70,990,000
Market Cap$61.75 million
IntelGenx Technologies (OTCMKTS:IGXT) Frequently Asked Questions
What is IntelGenx Technologies' stock symbol?
IntelGenx Technologies trades on the OTCMKTS under the ticker symbol "IGXT."
How were IntelGenx Technologies' earnings last quarter?
IntelGenx Technologies Corp. (OTCMKTS:IGXT) announced its quarterly earnings data on Thursday, August, 9th. The company reported ($0.04) earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.04). The company had revenue of $0.23 million for the quarter, compared to analysts' expectations of $0.10 million. IntelGenx Technologies had a negative net margin of 202.88% and a negative return on equity of 214.48%. View IntelGenx Technologies' Earnings History.
When is IntelGenx Technologies' next earnings date?
What price target have analysts set for IGXT?
3 equities research analysts have issued 12 month target prices for IntelGenx Technologies' stock. Their forecasts range from $2.00 to $3.00. On average, they expect IntelGenx Technologies' share price to reach $2.50 in the next twelve months. This suggests a possible upside of 273.1% from the stock's current price. View Analyst Price Targets for IntelGenx Technologies.
What is the consensus analysts' recommendation for IntelGenx Technologies?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IntelGenx Technologies in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IntelGenx Technologies.
Who are some of IntelGenx Technologies' key competitors?
Some companies that are related to IntelGenx Technologies include Ocular Therapeutix (OCUL), Sienna Biopharmaceuticals (SNNA), Ardelyx (ARDX), Kamada (KMDA), Bellicum Pharmaceuticals (BLCM), ASLAN PHARMACEUTICALS ADR REP 5 (ASLN), Strongbridge Biopharma (SBBP), Acer Therapeutics (ACER), Melinta Therapeutics (MLNT), BioDelivery Sciences International (BDSI), Protagonist Therapeutics (PTGX), Aeglea Bio Therapeutics (AGLE), Affimed (AFMD), Calithera Biosciences (CALA) and Xenon Pharmaceuticals (XENE).
Who are IntelGenx Technologies' key executives?
IntelGenx Technologies' management team includes the folowing people:
- Dr. Horst G. Zerbe, Founder, Chairman, CEO, Pres & Chairman of Scientific Advisory Board (Age 71)
- Mr. Andre Godin CPA, CA, Exec. VP & CFO (Age 54)
- Dr. Dana Matzen, VP of Bus. & Corp. Devel. (Age 40)
- Ms. Nadine Paiement, Vice-Chair of Scientific Advisory Board and VP of R&D (Age 41)
- Ms. Ingrid Zerbe, Co-Founder & Corp. Sec. (Age 64)
How do I buy shares of IntelGenx Technologies?
Shares of IGXT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is IntelGenx Technologies' stock price today?
One share of IGXT stock can currently be purchased for approximately $0.67.
How big of a company is IntelGenx Technologies?
IntelGenx Technologies has a market capitalization of $61.75 million and generates $5.20 million in revenue each year. The company earns $-3,050,000.00 in net income (profit) each year or ($0.04) on an earnings per share basis. IntelGenx Technologies employs 35 workers across the globe.
What is IntelGenx Technologies' official website?
How can I contact IntelGenx Technologies?
IntelGenx Technologies' mailing address is 6420 ABRAMS, VILLE SAINT LAURENT A8, H4S 1Y2. The company can be reached via phone at 514-331-7440 or via email at [email protected]
MarketBeat Community Rating for IntelGenx Technologies (OTCMKTS IGXT)
MarketBeat's community ratings are surveys of what our community members think about IntelGenx Technologies and other stocks. Vote "Outperform" if you believe IGXT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IGXT will underperform the S&P 500 over the long term. You may vote once every thirty days.
